Developing an effective vaccine for herpes simplex virus
Researchers have identified key differences between HSV-1 and HSV-2 and have developed monoclonal antibodies that could treat neonatal infections.
List view / Grid view
Researchers have identified key differences between HSV-1 and HSV-2 and have developed monoclonal antibodies that could treat neonatal infections.
Messenger RNA (mRNA) may be the ‘skeleton key’ that unlocks the door to fight latent viral infections that have plagued researchers for generations. Dr Sandeep Basnet, Director, Clinical Development at Moderna Therapeutics explores modern vaccine development and why mRNA is taking centre stage.
Mammalian target of rapamycin complex 2 (mTORC2) was found to prevent brain damage in mice infected with herpes simplex virus 1 (HSV-1).
Researchers have unravelled the viral transcriptome and translatome of the herpes simplex virus (HSV-1) to aid disease research and immunotherapy.